Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S.

The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...

U.S FDA has accepted IND application for COMP360 in PTSD, enabling the initiation of a Phase 2b/3 (COMP202) clinical trial in patients living with PTSD.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic ...

Compass Pathways has entered its seventh U.S. strategic collaboration with Radial Health. Radial Health operates in five ...

Compass Pathways (CMPS), on Wednesday, said the U.S. Food and Drug Administration (FDA) has accepted its Investigational New ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

Compass Pathways reported operating expenses of $48.4 million, slightly above Canaccord's estimate of $48 million. Kulkarni highlighted that Compass Pathways is nearing completion of its COMP005 Phase ...

In other recent news, Compass Pathways has been making significant strides in its operations and development programs. RBC Capital initiated coverage on Compass Pathways shares, assigning an ...

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 COMP006 data will now be announced after 26-week time point, expected in ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20251104736485/en/ ...

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced ...